Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. - Wikidata - awgldk - TriplyDB

Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study.

Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study.

http://www.wikidata.org/entity/Q35195035

about

Drug-induced diabetes mellitus The role of protease inhibitors in the pathogenesis of HIV-associated lipodystrophy: cellular mechanisms and clinical implications Effect of rosiglitazone and metformin on insulin resistance in patients infected with human immunodeficiency virus receiving highly active antiretroviral therapy containing protease inhibitor: randomized prospective controlled clinical trial Pharmacokinetic and metabolic effects of American ginseng (Panax quinquefolius) in healthy volunteers receiving the HIV protease inhibitor indinavir.Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study).Dyslipidaemia and dysglycaemia in HIV-infected patients on highly active anti-retroviral therapy in Kumasi Metropolis Severe impairment of endothelial function with the HIV-1 protease inhibitor indinavir is not mediated by insulin resistance in healthy subjects.Antiretroviral therapy in the clinic Antiretroviral therapy exposure and insulin resistance in the Women's Interagency HIV study.Impact of randomized antiretroviral therapy initiation on glucose metabolism Direct comparison of the acute in vivo effects of HIV protease inhibitors on peripheral glucose disposal Lipodystrophy defined by Fat Mass Ratio in HIV-infected patients is associated with a high prevalence of glucose disturbances and insulin resistance.Risk of diabetes mellitus in persons with and without HIV: a Danish nationwide population-based cohort study.A structural basis for the acute effects of HIV protease inhibitors on GLUT4 intrinsic activity.HIV protease inhibitors acutely impair glucose-stimulated insulin release.Hypertriglyceridemia, Metabolic Syndrome, and Cardiovascular Disease in HIV-Infected Patients: Effects of Antiretroviral Therapy and Adipose Tissue Distribution.Boosting dose ritonavir does not alter peripheral insulin sensitivity in healthy HIV-seronegative volunteers.The acute effects of HIV protease inhibitors on insulin suppression of glucose production in healthy HIV-negative men.HIV therapy, metabolic syndrome, and cardiovascular risk.Effects of ritonavir and amprenavir on insulin sensitivity in healthy volunteers.Contribution of metabolic and anthropometric abnormalities to cardiovascular disease risk factors Cardiovagal autonomic function in HIV-infected patients with unsuppressed HIV viremia.Molecular Mechanisms for Altered Glucose Homeostasis in HIV Infection Single-dose lopinavir-ritonavir acutely inhibits insulin-mediated glucose disposal in healthy volunteers.Impact of switching antiretroviral therapy on lipodystrophy and other metabolic complications: a review.Update on HIV lipodystrophy.Metabolic abnormalities and body composition of HIV-infected children on Lopinavir or Nevirapine-based antiretroviral therapy.Cellular mechanisms of insulin resistance, lipodystrophy and atherosclerosis induced by HIV protease inhibitors.Antiretroviral Drug Levels and Interactions Affect Lipid, Lipoprotein, and Glucose Metabolism in HIV-1 Seronegative Subjects: A Pharmacokinetic-Pharmacodynamic Analysis Dysregulation of glucose metabolism in HIV patients: epidemiology, mechanisms, and management.Treatment of dyslipidaemia in HIV-infected persons.Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks.A review of the aetiology of dyslipidaemia and hyperlipidaemia in patients with HIV.HIV and highly active antiretroviral therapy: dyslipidemia, metabolic aberrations, and cardiovascular risk.Approach to the human immunodeficiency virus-infected patient with lipodystrophy Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men.Potential of Spirulina Platensis as a Nutritional Supplement in Malnourished HIV-Infected Adults in Sub-Saharan Africa: A Randomised, Single-Blind Study.HIV infection and glycemic response to newly initiated diabetic medical therapy.Hormonal contraception and HIV-positive women: metabolic concerns and management strategies Effects of once-daily darunavir/ritonavir versus atazanavir/ritonavir on insulin sensitivity in HIV-infected persons over 48 weeks: results of an exploratory substudy of METABOLIK, a phase 4, randomized trial.

P2860

Q22306015-D8EF9D0B-0F3C-4919-B3E7-6327D20B09C5 Q24598812-C6125516-35DD-49E1-A98C-C8DCDE640E90 Q24645513-E1B10458-F075-439B-9C76-E8536D1D2059 Q33361454-025CCFE7-BD2D-4D7D-BA89-4BD4A874F114 Q33404972-6D7C4864-6D57-44FA-8BA8-CBB474ABBF39 Q33751516-56346D16-FB4B-4D22-B8E7-5AC50CC6D0CC Q33816114-A0C4526D-2A2A-405C-9B86-C2DCAC826B6F Q33877347-6465A8BB-8C77-40D4-9646-37FA8FC8D63C Q33927532-A8FD612E-0199-4691-AD1F-10E256FEECA9 Q34205448-5A0EF698-46E4-48D0-9CD5-8462F3EEC650 Q34333596-74823BB3-7415-4C92-891A-60163C9CA3F2 Q34367498-D373306B-7066-43FD-81FE-82408E760ABD Q34415980-617BD690-0685-4C92-9695-EB74A3592D37 Q34455618-EB05FE0F-85CF-4B74-AE04-3AEE96254859 Q34455624-F3646F7A-0C6E-431A-A3B9-626981DB1E98 Q35176441-BDEA811E-2988-4D89-BADD-55672CBE4983 Q35188653-39275459-F76B-423A-B582-51878C43197B Q35188665-27071F86-48A9-4152-B5F8-90A553540A8B Q35194399-BA5DBEE0-984E-45E0-A820-2F7C0226F4FC Q35196656-7206EA4B-4954-4CB3-9566-FB53B430E759 Q35206635-75D021D4-2A39-4BE4-A91C-F04A6E7AD691 Q35218159-EEC5EBD6-1D1D-42C5-B26C-FCFC2294799B Q35250665-338AE7CC-7DCD-41C0-9BF8-2B14573167A9 Q35498847-BAF1A6CB-25DE-4495-B333-A38CAD51D7D5 Q35805765-E60E9575-728C-46AE-80D1-17FD71AAB654 Q35833512-DFF70490-88D4-4E80-AA90-366AFB308C9D Q35945312-CA56AD40-3C2B-49D9-AF72-998D569402E1 Q36011828-627DBB18-0C34-4350-BCFC-BCCD7DA8FC7E Q36145648-789A968C-439A-472B-976C-D8814B5E6856 Q36158019-75084575-BFE8-4EBF-A249-B5BC912A0970 Q36222023-877FCED7-F07F-4D2B-919A-7E4E261246A7 Q36250357-AF0721A1-139B-46C6-816A-C762249F01B7 Q36292303-2A087CB7-823E-4B79-911B-C838FB4CF41D Q36773367-BA41BA7F-03EF-4799-A599-32E4824514A0 Q36834945-C024D4CC-8397-4B6D-9F47-90F4F8FD2E43 Q37057982-8ADC2E42-C9CC-4B19-A05E-6B198C68F35D Q37082824-04D15920-C544-4FC9-826C-4F7121E19177 Q37178529-1C983035-6AF6-4540-A33A-EF52E3BCB2E4 Q37202281-97366724-F88A-413A-BEB2-3997E57C8F37 Q37250997-E4D51D06-360D-4B4E-BA1B-964AAA31AA7A

P2860

Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study.

http://www.wikidata.org/entity/Q35195035

description

2002 nî lūn-bûn

@nan

2002 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի մարտին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Indinavir acutely inhibits ins ...... zed, placebo-controlled study.

@ast

Indinavir acutely inhibits ins ...... zed, placebo-controlled study.

@en

type

label

Indinavir acutely inhibits ins ...... zed, placebo-controlled study.

@ast

Indinavir acutely inhibits ins ...... zed, placebo-controlled study.

@en

prefLabel

Indinavir acutely inhibits ins ...... zed, placebo-controlled study.

@ast

Indinavir acutely inhibits ins ...... zed, placebo-controlled study.

@en

P1433

Q35195035-D571B5BC-F3AD-43EF-85A0-AD1EF6C23B83

P1476

Q35195035-C87675DD-3902-4325-B6D2-1C1284FD2501

P2093

Q35195035-02C45840-3A02-48F0-8DD2-407A97E60C15

Q35195035-3802C64A-15C5-4CF6-8C67-4953121BB474

Q35195035-3DCAC810-97D7-4CBC-B917-273094AF0D12

Q35195035-9E96C0CF-1910-43A2-AC20-A79627991853

Q35195035-B1AA447C-7B1B-4A93-8B4B-04C66A2E8332

Q35195035-C64B20D5-8341-4EFA-B125-5F4E6A7CDC77

Q35195035-D71B87B4-A9E1-432E-A47A-F3129BF09D37

Q35195035-F09290C2-7EAF-4A09-A792-6641D0EB0A89

P2860

Q35195035-0154EB99-6B73-4B0C-AAD6-27B5A116BE7C

Q35195035-07741D85-2575-4CA8-B1BB-6BB95EB027B4

Q35195035-0E96751B-667C-4093-9C9D-0960B0DFA85E

Q35195035-183A5A9C-8002-476B-AA8E-1761B0B140A9

Q35195035-21CF061D-E80B-449B-BFC1-FCF993B16FA1

Q35195035-2FA85ECA-0045-494A-8F2B-75C9CED23F39

Q35195035-4493B747-7962-45F2-A66B-0F4CE550B4DB

Q35195035-4C74ED20-0627-45CF-B761-AD0D43CBC692

Q35195035-510ED5EC-85FA-4386-86F3-9771D27B5E3C

Q35195035-533D4611-0355-44B0-9B5E-AFBF3DF415ED

P304

Q35195035-826E144B-2270-4005-8505-BEF3D152FCF7

P31

Q35195035-17F816FE-CFEF-4861-8578-5D43D1A67745

P356

Q35195035-02DA4AA2-05C6-48A3-AF1C-FD7C9754893E

P407

Q35195035-4D7DC110-3EAD-41DB-9D7E-A34C6486B6FA

P433

Q35195035-43C33AC8-2BED-4422-A81C-F80C1B5D0A52

P478

Q35195035-D08CA701-6889-4E8D-A352-3E31764BCF53

P577

Q35195035-405AEC0D-58F5-4F38-BD39-38CB041FA948

P5875

Q35195035-E96373BE-3E0C-4B2B-B3C2-077F4BC500D5

P698

Q35195035-A74F7CF4-2055-4C39-AB9D-0CAD4D5E81E0

P921

Q35195035-24C2719A-183A-4B15-8A7D-4F28C43F723C

Q35195035-B1BC3DBF-493D-413C-A98C-614318D52E02

P932

Q35195035-D62E0DE8-3930-4D36-AC5C-C40526487C46

P356

00002030-200203290-00002

P1433

P1476

Indinavir acutely inhibits ins ...... zed, placebo-controlled study.

@en

P2093

Carl Grunfeld

http://www.w3.org/2001/XMLSchema#string

Francesca T Aweeka

http://www.w3.org/2001/XMLSchema#string

Jean-Marc Schwarz

http://www.w3.org/2001/XMLSchema#string

Joan C Lo

http://www.w3.org/2001/XMLSchema#string

Kathleen Mulligan

http://www.w3.org/2001/XMLSchema#string

Morris Schambelan

http://www.w3.org/2001/XMLSchema#string

Mustafa A Noor

http://www.w3.org/2001/XMLSchema#string

Tara Seneviratne

http://www.w3.org/2001/XMLSchema#string

P2860

Obesity and insulin resistance

Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver

Metabolic effects of indinavir in healthy HIV-seronegative men

The HIV protease inhibitor nelfinavir induces insulin resistance and increases basal lipolysis in 3T3-L1 adipocytes.

Safety, pharmacokinetics, and antiretroviral activity of the potent, specific human immunodeficiency virus protease inhibitor nelfinavir: results of a phase I/II trial and extended follow-up in patients infected with human immunodeficiency virus.

Glucose transporters and insulin action--implications for insulin resistance and diabetes mellitus.

Disorders of glucose metabolism in patients infected with human immunodeficiency virus.

Glucose clamp technique: a method for quantifying insulin secretion and resistance.

Insulin resistance in HIV protease inhibitor-associated diabetes.

The insulin-sensitive glucose transporter.

P304

F1-8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/00002030-200203290-00002

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2002-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11402474

http://www.w3.org/2001/XMLSchema#string

P698

11964551

http://www.w3.org/2001/XMLSchema#string

P921

P932

3166537

http://www.w3.org/2001/XMLSchema#string